Spots Global Cancer Trial Database for Letrozole or Laparoscopic Ovarian Diathermy for Women With CC Resistant Polycystic Ovary Syndrome.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Letrozole or Laparoscopic Ovarian Diathermy for Women With CC Resistant Polycystic Ovary Syndrome.
Official Title: Letrozole Versus Laparoscopic Ovarian Diathermy for Ovulation Induction in Clomiphene-resistant Women With Polycystic Ovary Syndrome
Study ID: NCT00956267
Conditions
Study Description
Brief Summary: The purpose of this study is to compare and determine the efficacy of letrozole administration to that of laparoscopic ovarian diathermy (LOD) in infertile women with Polycystic ovary syndrome(PCOS)not responding to treatment with Clomiphene alone.
Detailed Description: In the letrozole group, withdrawal bleeding was achieved using 10 mg of dydrogesterone tablets for 10 days before stimulation, then 2.5 mg of letrozole oral tablets (Femara; Novartis Pharma Services, Switzerland) daily from day 3 of the menses for 5 days up to six cycles. All patients in the control group underwent laparoscopic ovarian diathermy, then followed up for 6 months.
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Mansoura University Hospitals,OB/GYN department, Mansoura, Dakahlia Governorate, Egypt
Contact Details
Name: Hatem Abu Hashim, MD. MRCOG
Affiliation: Mansoura University Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Abdel Maged Mashaly, MD
Affiliation: Mansoura University Hospital
Role: STUDY_DIRECTOR
Name: Ahmed Badawy, MD.PhD.
Affiliation: Mansoura University Hospital
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
